Answers are grounded in this paper and cite their sources.
Nuclear factor interleukin-3-regulated (NFIL3) is a basic domain leucine zipper transcription factor. Initially characterized as a repressor of gene transcription, NFIL3 can also act as a transcriptional activator, depending on the cellular context. Nascent polypeptide Associated Complex and coregulator alpha (NACA), a downstream effector of parathyroid hormone (PTH) signaling in bone, mediates increases in Nfil3 gene expression following PTH treatment. The physiological role of NFIL3 in bone and PTH response has not been addressed in vivo. In this study we demonstrate the importance of NFIL3 for bone biology and the PTH osteoanabolic effect. Using mice deficient for Nfil3 specifically in mature osteoblasts and osteocytes (Nfil3fl/fl;BGLAP-Cre, Nfil3osb-/-), we show that Nfil3 inactivation impaired osteoblast differentiation and mineralization ex vivo, decreased cortical bone quality and blunted the osteoanabolic response to PTH in vivo. We also demonstrate that NFIL3 bound to and activated osteoblastic marker genes. In osteoblasts, ChIP-seq analysis against NFIL3 and histone acetylation and methylation marks indicated that NFIL3 binding was associated with increased acetylation marks on target promoters. Mechanistically, NFIL3 interacted with CREB and CREB binding protein (CBP) to promote histone acetylation and gene transcription. In addition to their bone phenotype, Nfil3osb-/- mice displayed an impaired glycemic control, increased energy expenditure, and decreased food intake. This phenotype was partially caused by insulin resistance in osteoblasts, resulting in decreased serum osteocalcin levels. This study clearly establishes that NFIL3 contributes to bone formation and PTH and insulin responses in vivo.
No takes yet. Share an insight, caveat, or question.
Rifai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: